Skip to main content
SpringerLink
Log in

Minimal Residual Disease and Circulating Tumor Cells in Breast Cancer: Open Questions for Research

  • Chapter
  • First Online:
Minimal Residual Disease and Circulating Tumor Cells in Breast Cancer

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 195))

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Pantel K, Brakenhoff RH, Brandt B (2008) Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 8:329–340

    Article  PubMed  CAS  Google Scholar 

  2. Ignatiadis M, Reinholz MM (2011) Minimal residual disease and circulating tumor cells in breast cancer. Breast Cancer Res 13:222

    Article  PubMed  CAS  Google Scholar 

  3. Comen E, Norton L (2012) Self seeding in cancer. In: Ignatiadis M et al (eds) Minimal residual disease and circulating tumor cells in breast cancer, recent results in cancer research, vol 195. Springer-Verlag. doi:10.1007/978-3-642-28160-0_1

  4. Kim MY, Oskarsson T, Acharyya S, Nguyen DX, Zhang XH, Norton L, Massague J (2009) Tumor self-seeding by circulating cancer cells. Cell 139:1315–1326

    Article  PubMed  Google Scholar 

  5. Bragado P, Sosa MS, Keely P, Condeelis J, Agguire-Ghiso JA (2012) Microenvironments dictating tumor cell dormancy. In: Ignatiadis M et al (eds) Minimal residual disease and circulating tumor cells in breast cancer, recent results in cancer research, vol 195. Springer-Verlag. doi:10.1007/978-3-642-28160-0_1

  6. Uhr JW, Pantel K (2011) Controversies in clinical cancer dormancy. Proc Natl Acad Sci USA 108:12396–12400

    Article  PubMed  CAS  Google Scholar 

  7. Aguirre-Ghiso JA (2007) Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 7: 834–846

    Google Scholar 

  8. Goss PE, Chambers AF (2010) Does tumour dormancy offer a therapeutic target? Nat Rev Cancer 10:871–877

    Article  PubMed  CAS  Google Scholar 

  9. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, Tibbe AG, Uhr JW, Terstappen LW (2004) Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 10:6897–6904

    Article  PubMed  Google Scholar 

  10. Hoeppener A, Swennenhuis JF, Terstappen LWMM (2012) Immunomagnetic separation technologies. In: Ignatiadis M et al (eds) Minimal residual disease and circulating tumor cells in breast cancer, recent results in cancer research, vol 195. Springer-Verlag. doi:10.1007/978-3-642-28160-0_1

  11. Bhagat AA, Hou HW, Li LD, Lim CT, Han J (2011) Pinched flow coupled shear-modulated inertial microfluidics for high-throughput rare blood cell separation. Lab Chip 11:1870–1878

    Article  PubMed  CAS  Google Scholar 

  12. Bhagat AAS, Lim CT (2012) Microfluidic technologies for the isolation of CTCs. In: Ignatiadis M et al (eds) Minimal residual disease and circulating tumor cells in breast cancer, recent results in cancer research, vol 195. Springer-Verlag. doi:10.1007/978-3-642-28160-0_1

  13. Alix-Panabieres C, Vendrell JP, Pelle O, Rebillard X, Riethdorf S, Muller V, Fabbro M, Pantel K (2007) Detection and characterization of putative metastatic precursor cells in cancer patients. Clin Chem 53:537–539

    Article  PubMed  CAS  Google Scholar 

  14. Alix-Panabieres C (2012) EPISPOT. In: Ignatiadis M et al (eds) Minimal residual disease and circulating tumor cells in breast cancer, recent results in cancer research, vol 195. Springer-Verlag. doi:10.1007/978-3-642-28160-0_1

  15. Krivacic RT, Ladanyi A, Curry DN, Hsieh HB, Kuhn P, Bergsrud DE, Kepros JF, Barbera T, Ho MY, Chen LB, Lerner RA, Bruce RH (2004) A rare-cell detector for cancer. Proc Natl Acad Sci USA 101:10501–10504

    Article  PubMed  CAS  Google Scholar 

  16. Dietz L, Bruce R (2012) Advances in optical technologies for rare cell detection and characterization. In: Ignatiadis M et al (eds) Minimal residual disease and circulating tumor cells in breast cancer, recent results in cancer research, vol 195. Springer-Verlag. doi:10.1007/978-3-642-28160-0_1

  17. Zheng S, Lin HK, Lu B, Williams A, Datar R, Cote RJ, Tai YC (2011) 3D microfilter device for viable circulating tumor cell (CTC) enrichment from blood. Biomed Microdevices 13:203–213

    Article  PubMed  Google Scholar 

  18. Williams A, Balic M, Datar R, Cote RJ (2012) Size-based enrichment technologies for CTC detection and characterization. In: Ignatiadis M et al (eds) Minimal residual disease and circulating tumor cells in breast cancer, recent results in cancer research, vol 195. Springer-Verlag. doi:10.1007/978-3-642-28160-0_1

  19. Yang L, Lang JC, Balasubramanian P, Jatana KR, Schuller D, Agrawal A, Zborowski M, Chalmers JJ (2009) Optimization of an enrichment process for circulating tumor cells from the blood of head and neck cancer patients through depletion of normal cells. Biotechnol Bioeng 102:521–534

    Article  PubMed  CAS  Google Scholar 

  20. Lustberg M, Jatana KR, Zborowski M, Chalmers JJ (2012) Emerging technologies for CTC detection based on depletion of normal cells. In: Ignatiadis M et al (eds) Minimal residual disease and circulating tumor cells in breast cancer, recent results in cancer research, vol 195. Springer-Verlag. doi:10.1007/978-3-642-28160-0_1

  21. Markou A, Strati A, Malamos N, Georgoulias V, Lianidou ES (2011) Molecular characterization of circulating tumor cells in breast cancer by a liquid bead array hybridization Assay. Clin Chem. doi:10.1373/clinchem.2010.154328

  22. Lianidou E, Markou A (2012) Molecular assays for the detection and characterization of CTCs. In: Ignatiadis M et al (eds) Minimal residual disease and circulating tumor cells in breast cancer, recent results in cancer research, vol 195. Springer-Verlag. doi:10.1007/978-3-642-28160-0_1

  23. Sieuwerts AM, Mostert B, Bolt-de Vries J, Peeters DJ, de Jongh F, Stouthard J, van Galen A, Dirix LY, van Dam PA, de Weerd V, Kraan, J, van der SP, Ramirez-Moreno R, van Deurzen C, Smid M, Yu J, Jiang J, Wang Y, Gratama J, Sleijfer S, Foekens JA, Martens JW (2011) mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients. Clin Cancer Res 17(11):3600–3618

    Google Scholar 

  24. Talasaz AH, Powell AA, Huber DE, Berbee JG, Roh KH, Yu W, Xiao W, Davis MM, Pease RF, Mindrinos MN, Jeffrey SS, Davis RW (2009) Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood using a magnetic sweeper device. Proc Natl Acad Sci USA 106:3970–3975

    Article  PubMed  CAS  Google Scholar 

  25. Sieuwerts AM, Jeffrey SS (2012) Multiplex Molecular Analysis of CTCs. In: Ignatiadis M et al (eds) Minimal residual disease and circulating tumor cells in breast cancer, recent results in cancer research, vol 195. Springer-Verlag. doi:10.1007/978-3-642-28160-0_1

  26. Alix-Panabieres C, Schwarzenbach H, Pantel K (2012) Circulating Tumor Cells and Circulating Tumor DNA. Annu Rev Med 63:199–215

    Article  Google Scholar 

  27. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351:781–791

    Article  PubMed  CAS  Google Scholar 

  28. Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse M, Mitchell E, Miller MC, Doyle GV, Tissing H, Terstappen LW, Meropol NJ (2008) Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 26:3213–3221

    Article  PubMed  Google Scholar 

  29. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, Doyle GV, Terstappen LW, Pienta KJ, Raghavan D (2008) Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 14:6302–6309

    Article  PubMed  Google Scholar 

  30. Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC, Schlimok G, Diel IJ, Gerber B, Gebauer G, Pierga JY, Marth C, Oruzio D, Wiedswang G, Solomayer EF, Kundt G, Strobl B, Fehm T, Wong GY, Bliss J, Vincent-Salomon A, Pantel K (2005) A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 353:793–802

    CAS  Google Scholar 

  31. Janni W, Kasprowicz N, Scholz C, Rack B, Hepp P (2012) Bone marrow Disseminated Tumor Cells. In: Ignatiadis M et al (eds) Minimal residual disease and circulating tumor cells in breast cancer, recent results in cancer research, vol 195. Springer-Verlag. doi:10.1007/978-3-642-28160-0_1

  32. Janni W, Vogl FD, Wiedswang G, Synnestvedt M, Fehm T, Juckstock J, Borgen E, Rack B, Braun S, Sommer H, Solomayer E, Pantel K, Nesland J, Friese K, Naume B (2011) Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse—a European pooled analysis. Clin Cancer Res 17:2967–2976

    Article  PubMed  Google Scholar 

  33. Giordano A, Cristofanilli M (2011) Circulating Tumor Cells in Metastatic Breast Cancer. In: Ignatiadis M et al (eds) Minimal residual disease and circulating tumor cells in breast cancer, recent results in cancer research, vol 195. Springer-Verlag. doi:10.1007/978-3-642-28160-0_1

  34. Pierga JY, Hajage D, Bachelot T, Delaloge S, Brain E, Campone M, Dieras V, Rolland E, Mignot L, Mathiot C, Bidard FC (2011) High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. Ann Oncol 6(6):1006–1015

    Google Scholar 

  35. Saloustros E, Mavroudis D (2012) CTCs in early breast cancer using reverse transcriptase polymerase chain reaction for Cytokeratin-19. In: Ignatiadis M et al (eds) Minimal residual disease and circulating tumor cells in breast cancer, recent results in cancer research, vol 195. Springer-Verlag. doi:10.1007/978-3-642-28160-0_1

  36. Xenidis N, Perraki M, Kafousi M, Apostolaki S, Bolonaki I, Stathopoulou A, Kalbakis K, Androulakis N, Kouroussis C, Pallis T, Christophylakis C, Argyraki K, Lianidou ES, Stathopoulos S, Georgoulias V, Mavroudis D (2006) Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients. J Clin Oncol 24:3756–3762

    Article  PubMed  CAS  Google Scholar 

  37. Rack B, Andergassen U, Janni W, Neugebauer J (2012) Circulating Tumor Cells in primary breast cancer. In: Ignatiadis M et al (eds) Minimal residual disease and circulating tumor cells in breast cancer, recent results in cancer research, vol 195. Springer-Verlag. doi:10.1007/978-3-642-28160-0_1

  38. Rack B, Schindlbeck C, Andergassen U, Schneeweiss A, Zwingers T, Lichtenegger W, Beckmann M, Sommer H, Pantel K, Janni W (2010) Use of circulating tumor cells (CTC) in peripheral blood of breast cancer patients before and after adjuvant chemotherapy to predict risk for relapse: The SUCCESS trial. J Clin Oncol 28:7s, (suppl; abstr 1003)

    Google Scholar 

  39. Hartkopf AD, Banys M, Fehm T(2012) HER2-positive DTCs/CTCs in breast cancer. In: Ignatiadis M et al (eds) Minimal residual disease and circulating tumor cells in breast cancer, recent results in cancer research, vol 195. Springer-Verlag. doi:10.1007/978-3-642-28160-0_1

  40. Braun S, Schlimok G, Heumos I, Schaller G, Riethdorf L, Riethmuller G, Pantel K (2001) ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients. Cancer Res 61:1890–1895

    PubMed  CAS  Google Scholar 

  41. Meng S, Tripathy D, Shete S, Ashfaq R, Haley B, Perkins S, Beitsch P, Khan A, Euhus D, Osborne C, Frenkel E, Hoover S, Leitch M, Clifford E, Vitetta E, Morrison L, Herlyn D, Terstappen LW, Fleming T, Fehm T, Tucker T, Lane N, Wang J, Uhr J (2004) HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci USA 101:9393–9398

    Article  PubMed  CAS  Google Scholar 

  42. Taube S, Lively T (2012) Challenges in drug and biomarker co-development. In: Ignatiadis M et al (eds) Minimal residual disease and circulating tumor cells in breast cancer, recent results in cancer research, vol 195. Springer-Verlag. doi:10.1007/978-3-642-28160-0_1

  43. Punnoose E, Lackner MR (2012) Challenges and opportunities in the use of CTCs for companion diagnostic development. In: Ignatiadis M et al (eds) Minimal residual disease and circulating tumor cells in breast cancer, recent results in cancer research, vol 195. Springer-Verlag. doi:10.1007/978-3-642-28160-0_1

  44. Taube SE, Clark GM, Dancey JE, McShane LM, Sigman CC, Gutman SI (2009) A perspective on challenges and issues in biomarker development and drug and biomarker codevelopment. J Natl Cancer Inst 101:1453–1463

    Article  PubMed  Google Scholar 

  45. Diamandis EP, Pantel K, Scher HI, Terstappen L, Lianidou E (2011) Circulating Cancer Cells and Their Clinical Applications. Clin Chem 57:1478–1484

    Article  PubMed  CAS  Google Scholar 

  46. Mancuso P, Calleri A, Bertolini F (2012) Circulating Endothelial Cells and Circulating Endothelial Progenitors. In: Ignatiadis M et al (eds) Minimal residual disease and circulating tumor cells in breast cancer, recent results in cancer research, vol 195. Springer-Verlag. doi:10.1007/978-3-642-28160-0_1

  47. Calleri A, Bono A, Bagnardi V, Quarna J, Mancuso P, Rabascio C, Dellapasqua S, Campagnoli E, Shaked Y, Goldhirsch A, Colleoni M, Bertolini F (2009) Predictive potential of angiogenic growth factors and circulating endothelial cells in breast cancer patients receiving metronomic chemotherapy Plus Bevacizumab. Clin Cancer Res 15:7652–7657

    Article  PubMed  CAS  Google Scholar 

  48. Cooke S Campbell P (2012) Circulating DNA and next generation sequencing. In: Ignatiadis M et al (eds) Minimal residual disease and circulating tumor cells in breast cancer, recent results in cancer research, vol 195. Springer-Verlag. doi:10.1007/978-3-642-28160-0_1

  49. McBride DJ, Orpana AK, Sotiriou C, Joensuu H, Stephens PJ, Mudie LJ, Hamalainen E, Stebbings LA, Andersson LC, Flanagan AM, Durbecq V, Ignatiadis M, Kallioniemi O, Heckman CA, Alitalo K, Edgren H, Futreal PA, Stratton MR, Campbell PJ (2010) Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors. Genes Chromosomes Cancer 49:1062–1069

    Article  PubMed  CAS  Google Scholar 

  50. Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Newell J, Kerin MJ (2010) Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg 251:499–505

    Article  PubMed  Google Scholar 

  51. Cortez MA, Welsh JW, Calin GA (2012) Circulating microRNAS as non-invasive biomarkers in breast cancer. In: Ignatiadis M et al (eds) Minimal residual disease and circulating tumor cells in breast cancer, recent results in cancer research, vol 195. Springer-Verlag. doi:10.1007/978-3-642-28160-0_1

  52. Schwarzenbach H, Hoon DS, Pantel K (2011) Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 11:426–437

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology and Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Boulevard de Waterloo 125, 1000, Brussels, Belgium

    Michail Ignatiadis & Christos Sotiriou

  2. Zentrum für Experimentelle Medizin, Institut für Tumorbiologie, Universitätsklinikum Hamburg- Eppendorf, Martinistr. 52, 20246, Hamburg, Germany

    Klaus Pantel

Authors
  1. Michail Ignatiadis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christos Sotiriou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Klaus Pantel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Klaus Pantel .

Editor information

Editors and Affiliations

  1. , Breast Cancer Translational Res. Lab., Institut Jules Bordet, Boulevard de Waterloo 125, Brussels, 1000, Belgium

    Michail Ignatiadis

  2. , Breast Cancer Translational Res. Lab., Institut Jules Bordet, Boulevard de Waterloo 125, Brussels, 1000, Belgium

    Christos Sotiriou

  3. Zentrum für Experimentelle Medizin, Inst. Tumorbiologie, Universitätsklinikum Hamburg-Eppendorf, Martinistr. 52, Hamburg, 20246, Germany

    Klaus Pantel

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Ignatiadis, M., Sotiriou, C., Pantel, K. (2012). Minimal Residual Disease and Circulating Tumor Cells in Breast Cancer: Open Questions for Research. In: Ignatiadis, M., Sotiriou, C., Pantel, K. (eds) Minimal Residual Disease and Circulating Tumor Cells in Breast Cancer. Recent Results in Cancer Research, vol 195. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-28160-0_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-28160-0_1

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-28159-4

  • Online ISBN: 978-3-642-28160-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation